       Document 0221
 DOCN  M95A0221
 TI    Bacterial vaccine vectors and bacillus Calmette-Guerin.
 DT    9510
 AU    Cirillo JD; Stover CK; Bloom BR; Jacobs WR Jr; Barletta RG; Department
       of Microbiology and Immunology, Stanford University,; California, USA.
 SO    Clin Infect Dis. 1995 Apr;20(4):1001-9. Unique Identifier : AIDSLINE
       MED/95315345
 AB    Recent advances in biotechnology now allow a more modern approach to the
       development of vaccines, particularly that of recombinant vaccines.
       Bacterial vaccine vectors have the advantage over viral vectors in that
       the former have the ability to express a greater number of antigens in
       different forms. Although no recombinant bacterial vaccines are
       currently in use, bacillus Calmette-Guerin (BCG), Salmonella species,
       and Escherichia coli are being developed as vaccine vectors. We review
       plasmid systems and mutant strains developed for the expression of
       foreign antigens, with particular emphasis on those developed for BCG.
       We describe the development of antigen expression systems as well as the
       immune response elicited by recombinant BCG vaccine strains to bacterial
       and human immunodeficiency virus (HIV) antigens. A modified recombinant
       BCG carrier with selection for the stable maintenance of rDNA is
       proposed.
 DE    Administration, Oral  Antigens, Bacterial/BIOSYNTHESIS/IMMUNOLOGY
       Bacteria  Base Sequence  BCG Vaccine/*ADMINISTRATION & DOSAGE  Drug
       Carriers  DNA, Ribosomal  Human  Molecular Sequence Data
       Mycobacterium/IMMUNOLOGY  Mycobacterium Infections/PREVENTION & CONTROL
       Plasmids  Tuberculosis/*PREVENTION & CONTROL  Vaccines,
       Synthetic/ADMINISTRATION & DOSAGE  JOURNAL ARTICLE  REVIEW  REVIEW,
       TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

